Sensei Biotherapeutics (NASDAQ:FTH) Now Covered by Analysts at Raymond James Financial

Posted by Brian Himes on Jul 31st, 2026

Raymond James Financial started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) in a research report issued to clients and investors on Friday,Benzinga reports. The firm set an “outperform” rating and a $56.00 price target on the stock. Raymond James Financial’s price target suggests a potential upside of 94.31% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the stock. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target on the stock. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. BTIG Research reissued a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Finally, Leerink Partners started coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $54.89.

Read Our Latest Analysis on Sensei Biotherapeutics

Sensei Biotherapeutics Trading Down 0.4%

FTH stock opened at $28.82 on Friday. The firm has a market capitalization of $38.62 million, a price-to-earnings ratio of -0.20 and a beta of -0.26. Sensei Biotherapeutics has a 1 year low of $7.10 and a 1 year high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. As a group, analysts predict that Sensei Biotherapeutics will post -16.61 EPS for the current year.

Insider Activity

In related news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson bought 9,391 shares of the stock in a transaction on Wednesday, June 24th. The shares were acquired at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the purchase, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This represents a 53.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several large investors have recently made changes to their positions in FTH. Renaissance Technologies LLC increased its stake in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new position in Sensei Biotherapeutics in the 1st quarter worth $4,188,000. Finally, Vivo Capital LLC acquired a new stake in shares of Sensei Biotherapeutics in the first quarter valued at about $22,758,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.